HCV-related autoimmune disorders in HCV chronic infection

Clinica Terapeutica

Volumn 164, Issue SUPPL.4, 2013, Pages

  Ferrari, S M ^a   Fallahi, P ^a   Mancusi, C ^a   Colaci, M ^b   Manfredi, A ^b   Ferri, C ^b   Antonelli, Alessandro ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cytokines; Extrahepatic manifestations; HCV; Thyroid dysfunctions

Indexed keywords

AUTOIMMUNE DISEASE; DISEASE ASSOCIATION; HEPATITIS B; IMMUNOPATHOGENESIS; REVIEW; AUTOIMMUNE DISEASES; CHRONIC HEPATITIS C; COMPLICATION; HUMAN;

AUTOIMMUNE DISEASES; HEPATITIS C, CHRONIC; HUMANS;

EID: 84885799512     PISSN: 00099074     EISSN: 19726007     Source Type: Journal    
DOI: 10.7417/CT.2013.1594     Document Type: Review

References (116)

1. Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19:841-8
2. Hadziyannis SJ. Nonhepatic manifestations and combined diseases in HCV infection. Dig Dis Sci 1996; 41:63S-74S
3. Agnello V, De Rosa FG. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 2004; 40:341-52
4. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore). 2000; 79:47-56
5. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42:2204-12
6. Stefanova-Petrova DV, Tzvetanska AH, Naumova EJ, et al. Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients. World J Gastroenterol 2007; 13:6518-28
7. Galossi A, Guarisco R, Bellis L, et al. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis 2007; 16:65-73
8. Czaja AJ, Carpenter HA, Santrach PJ, et al. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol 1993; 18:342-52
9. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21:613-9
10. Muratori P, Muratori L, Guidi M, et al. Clinical impact of non-organ-specific autoantibodies on response to combined antiviral treatment in patients with hepatitis C. Clin Infect Di 2005; 40:501-7
11. Palazzi C, Buskila D, D'Angelo S, et al. Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases. Autoimmun Rev 2012; 11:659-63
12. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998; 158:1445-8
13. Huang MJ, Wu SS, Liaw YF. Thyroid abnormalities in patients with chronic viral hepatitis. Hepatol 1994; 20:1651-2
14. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995; 132:587-93
15. Quaranta JF, Tran A, Régnier D, et al. High prevalence of antibodies to hepatitis C virus (HCV) in patients with antithyroid autoantibodies. J Hepatol 1993; 18:136-8
16. Lenzi M, Johnson PJ, McFarlane IG, et al. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet 1991; 338:277-80
17. Prentice LM, Phillips DI, Sarsero D, et al. Geographical distribution of subclinical autoimmune thyroid disease in Britain: a study using highly sensitive direct assays for autoantibodies to thyroglobulin and thyroid peroxidase. Acta Endocrinol (Copenh) 1990; 123:493-8
18. Minelli R, Braverman LE, Giuberti T, et al. Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment. Clin Endocrinol (Oxf) 1997; 47:357-61
19. Antonelli A, Ferri C, Fallahi P. Thyroid cancer in patients with hepatitis C infection. JAMA 1999; 281:1588
20. Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004; 117(1):10-3
21. Ferri C, Zignego AL. Relation between infection and autoimmunity in mixed cryoglobulinemia. Curr Opin Rheumatol 2000; 12:53-60
22. Zignego AL, Ferri C, Giannelli F, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002; 137:571-80
23. Wong VS, Egner W, Elsey T, et al. Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection. Clin Exp Immunol 1996; 104:25-31
24. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282:938-41
25. De Re V, De Vita S, Marzotto A, et al. Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. Int J Cancer 2000; 87:211-6
26. Sansonno D, Lauletta G, Nisi L, et al. Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia. Clin Exp Immunol 2003; 133:275-82
27. Ferri C, Pileri S, Zignego AL. Hepatitis C virus infection and non-Hodgkin's lymphoma. In: Goedert J (ed). Infectious causes of cancer. Targets for intervention. The Human Press Inc, Totowa, New Jersey, 2000; 349-68
28. Zignego AL, Giannelli F, Marrocchi ME, et al. T(14;18) translocation in chronic hepatitis C virus infection. Hepatology. 2000; 31:474-9
29. Giannelli F, Moscarella S, Giannini C, et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 2003; 102:1196-201
30. Sansonno D, Carbone A, De Re V, et al. Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology (Oxford) 2007; 46:572-8
31. Sène D, Limal N, Ghillani-Dalbin P, et al. Hepatitis C virusassociated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology (Oxford) 2007; 46:65-9
32. Fabris M, Quartuccio L, Sacco S, et al. B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology (Oxford) 2007; 46:37-43
33. Sansonno D, Tucci FA, Troiani L, et al. Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis. Blood 2008; 112:1620-7
34. Saadoun D, Boyer O, Trébeden-Nègre H, et al. Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis. J Hepatol 2004; 41:1031-7
35. Loffreda S, Muratori P, Muratori L, et al. Enhanced monocyte Th1 cytokine production in HCV-infected cryoglobulinemic patients. J Hepatol 2003; 38:230-6
36. Patzwahl R, Meier V, Ramadori G, et al. Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppressionsubtractive hybridization. J Virol 2001; 75:1332-8
37. Mihm S, Schweyer S, Ramadori G. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN-gamma and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. J Med Virol 2003; 70:562-70
38. Matskevich AA, Strayer DS. Exploiting hepatitis C virus activation of NFkappaB to deliver HCV-responsive expression of interferons alpha and gamma. Gene Ther 2003; 10:1861-73
39. Murata M, Nabeshima S, Maeda N, et al. Increased frequency of IFN-gamma-producing peripheral CD8+ T cells with memory-phenotype in patients with chronic hepatitis C. J Med Virol 2002; 67:162-70
40. Itoh Y, Morita A, Nishioji K, Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels. J Viral Hepat 2001; 8:341-8
41. Antonelli A, Ferri C, Ferrari SM, et al. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev 2008; 8:18-23
42. Antonelli A, Ferri C, Galeazzi M, et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol 2008; 26:S39-47
43. Antonelli A, Ferri C, Fallahi P. Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy. Nat Rev Gastroenterol Hepatol 2009; 6:633-5
44. Apolinario A, Majano PL, Lorente R, et al. Gene expression profile of T-cell-specific chemokines in human hepatocytederived cells: evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins. J Viral Hepat 2005; 12:27-37
45. Antonelli A, Rotondi M, Fallahi P, et al. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 2004; 89:5496-9
46. Antonelli A, Fallahi P, Ferrari SM, et al. Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis. Mod Rheumatol 2012; 22:659-67
47. Antonelli A, Ferri C, Ferrari SM, et al. High serum levels of CXCL11 in mixed cryoglobulinemia are associated with increased circulating levels of interferon-ã. J Rheumatol 2011; 38:1947-52
48. Antonelli A, Ferri C, Ferrari SM, et al. Interleukin-1â, C-x-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis. J Interferon Cytokine Res 2010; 30:835-42
49. Antonelli A, Ferri C, Ferrari SM, et al. Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection. J Rheumatol 2010; 37:91-7
50. Antonelli A, Ferri C, Fallahi P, High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol 2008; 103:2488-94
51. Antonelli A, Ferri C, Fallahi P, CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C. Dig Liver Dis 2009; 41:42-8
52. Antonelli A, Ferri C, Ferrari SM, Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia. Arthritis Rheum 2009; 60:3841-7
53. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002; 46:741-7
54. Vasil'ev VI, Probatova NA, Varlamova EIu, et al. Prognostic implications of mixed monoclonal cryoglobulinemia in Sjogren's disease. Ter Arkh 2004; 76:61-8
55. Pillemer SR, Smith J, Fox PC, et al. Outcome measures for Sjögren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA. J Rheumatol 2005; 32:143-9
56. Ramos-Casals M, Brito-Zerón P, Yagüe J, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford). 2005; 44:89-94
57. Ferri C, Mascia MT. Cryoglobulinemic vasculitis. Curr Opin Rheumatol 2006; 18:54-63
58. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554-8
59. Ramos-Casals M, Loustaud-Ratti V, De Vita S, et al. Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore) 2005; 84:81-9
60. Zignego AL, Macchia D, Monti M, et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol 1992; 15:382-6
61. Lormeau C, Falgarone G, Roulot D, et al. Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine 2006; 73:633-8
62. De Vita S, Soldano F, Isola M, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 2011; 70:1183-90
63. Bombardieri M, Alessandri C, Labbadia G, et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther 2004; 6:R137-41
64. Ferri C, Govoni M, Calabrese L. The A, B, Cs of viral hepatitis in the biologic era. Curr Opin Rheumatol 2010; 22:443-50
65. Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008; 35:1944-9
66. Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010; 116:335-42
67. Himoto T, Nakai S, Kinekawa F, et al. Clinical characteristics of patients with hepatitis C virus-related chronic liver disease seropositive for anticentromere antibody. Dig Dis Sci 2009; 54:360-8
68. Moroi Y, Peebles C, Fritzler MJ, et al. Autoantibody to cen tromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 1980; 77:1627-31
69. Muro Y, Azuma N, Onouchi H, et al. Autoepitopes on autoantigen centromere protein-A (CENP-A) are restricted to the N-terminal region, which has no homology with histone H3. Clin Exp Immunol 2000; 120:218-23
70. Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatol 1993; 18:253-7
71. Metcalfe RA, Ball G, Kudesia G, et al. Failure to find an association between hepatitis C virus and thyroid autoimmunity. Thyroid 1997; 7:421-4
72. Boadas J, Rodríguez-Espinosa J, Enríquez J, et al. Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection. J Hepatol 1995; 22:611-5
73. Donati L, Antonelli A, Bertoni F, et al. Clinical picture of endemic cretinism in central Apennines (Montefeltro). Thyroid 1992; 2:283-90
74. Indolfi G, Stagi S, Bartolini E, et al. Thyroid function and antithyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol (Oxf). 2008; 68:117-21
75. Watanabe U, Hashimoto E, Hisamitsu T, et al. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994; 89:399-403
76. Carella C, Amato G, Biondi B, et al. Longitudinal study of antibodies against thyroid in patients undergoing interferonalpha therapy for HCV chronic hepatitis. Horm Res 1995; 44:110-4
77. Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996; 101:482-7
78. Marazuela M, García-Buey L, González-Fernández B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996; 44:635-42
79. Carella C, Mazziotti G, Morisco F, et al. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol 2002; 146:743-9
80. Antonelli A, Ferri C, Fallahi P, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid 2006; 16:563-72
81. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007; 297:2010-7
82. Antonelli A, Ferri C, Galeazzi M, et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol 2008; 26:S39-47
83. Goldman M, Lambert P, Tasiaux N, et al. Thyroid-stimulating immunoglobulins in mixed (type II) cryoglobulinemia associated with thyrotoxicosis. Arthritis Rheum 1987; 30:1318-9
84. Castellano Higuera A, Gonzáles Reimers E, Alarcó Hernández B, et al. Hypothyroidism, hemolytic anemia and cryoglobulinemia in a patient with hepatitis C virus infection: efficacy of treatment with alpha-interferon. Ann Med Interna 2003; 20:391-2
85. Antonelli A, Campatelli A, Di Vito A, et al. Comparison between ethanol sclerotherapy and emptying with injection of saline in treatment of thyroid cysts. Clin Investi 1994; 72:971-4
86. Antonelli A, Ferri C, Fallahi P, et al. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. QJM 2004; 97:499-506
87. Antonelli A, Ferri C, Fallahi P. Thyroid cancer in patients with hepatitis C infection. JAMA 1999; 281:1588
88. Montella M, Crispo A, Pezzullo L, et al. Is hepatitis C virus infection associated with thyroid cancer? A case-control study. Int J Cancer 2000; 87:611-2
89. Montella M, Crispo A, de Bellis G, et al. HCV and cancer: a case-control study in a high-endemic area. Liver 2001; 21:335-41
90. Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCVrelated mixed cryoglobulinemia patients. Clin Exp Rheumatol 2002; 20:693-6
91. Fiore E, Rago T, Latrofa F, et al. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer 2011; 18:429-37
92. Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid 2007; 17:447-51
93. Ferri C, Antonelli A, Mascia MT, et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 2007; 39:S13-21
94. Neri S, Antonelli A, Falaschi F, et al. Findings from high resolution computed tomography of the lung and pleura of symptom free workers exposed to amosite who had normal chest radiographs and pulmonary function tests. Occup Environ Med 1994; 51:239-43
95. Antonelli A, Bocci G, La Motta C, et al. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab 2011; 96:E288-96
96. Antonelli A, Ferri C, Ferrari SM, et al. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev 2008; 8:18-23
97. Antonelli A, Rotondi M, Fallahi P, et al. Increase of interferongamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf) 2006; 64:189-95
98. Antonelli A, Rotondi M, Fallahi P, et al. Iodine-131 given for therapeutic purposes modulates differently interferongamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 2007; 92:1485-90
99. Antonelli A, Fallahi P, Rotondi M, et al. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 2006; 93:1226-31
100. Antonelli A, Rotondi M, Fallahi P, et al. Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. Cytokine 2006; 34:32-8
101. Antonelli A, Ferrari SM, Fallahi P, et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009; 94:1803-9
102. Antonelli A, Fallahi P, Nesti C, et al. Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. Clin Exp Immunol 2001; 126:426-31
103. Gowans EJ. Distribution of markers of hepatitis C virus infection throughout the body. Semin Liver Dis 2000; 20:85-102
104. Bartolomé J, Rodríguez-Iñigo E, Quadros P, et al. Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection. J Med Virol 2008; 80:1588-94
105. Antonelli A, Fazzi P, Fallahi P, et al. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest 2006; 130:526-32
106. Antonelli A, Ferri C, Fallahi P, et al. Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. Metabolism 2008; 57:1270-7
107. Antonelli A, Ferri C, Ferrari SM, et al. The presence of autoimmune thyroiditis in mixed cryoglobulinemia patients is associated with high levels of circulating interleukin-6, but not of tumor necrosis factor-alpha. Clin Exp Rheumatol 2011; 29:S17-22
108. Ferri C, Antonelli A, Mascia MT, et al. B-cells and mixed cryoglobulinemia. Autoimmun Rev 2007; 7:114-20
109. Antonelli A, Fallahi P, Ferrari SM, et al. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. Diabet Med 2008; 25:1349-53
110. Antonelli A, Tuomi T, Nannipieri M, et al. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia 2002; 45:1298-306
111. Antonelli A, Baj G, Marchetti P, et al. Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. Diabetes 2001; 50:985-91
112. Antonelli A, Ferri C, Fallahi P, et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis--a longitudinal study. Rheumatology (Oxford) 2008; 47:45-9
113. Ramos-Casals M, García-Carrasco M, López-Medrano F, et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine (Baltimore) 2003; 82:87-96
114. Dufour JF, Pradat P, Ruivard M, et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases. Eur J Gastroenterol Hepatol 2009; 21:245-53
115. Panzer S, Seel E, Brunner M, et al. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol 2006; 77:513-7
116. Aref S, Sleem T, El Menshawy N, Ebrahiem L, et al. Antiplatelet antibodies contribute to thrombocytopenia associated with chronic hepatitis C virus infection. Hematol 2009; 14:277-81